MONALEESA-2 supports the evolving role of CDK4/6 inhibitors in addition to standard therapy for postmenopausal women with HR-positive, HER2- negative advanced breast cancer Back

To view this article, please confirm that you are a healthcare professional by clicking 'Confirm' below.